Wird geladen...
Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
PROSPER is an international Phase III trial demonstrating the beneficial role of enzalutamide, an androgen receptor antagonist, in prolonging metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. The trial showed that the median metastasis-free survival was 21.9 mo...
Gespeichert in:
| Veröffentlicht in: | Asian J Androl |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Medknow Publications & Media Pvt Ltd
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6413545/ https://ncbi.nlm.nih.gov/pubmed/30460933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/aja.aja_88_18 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|